Isoform-specific effects of apolipoprotein E on atherogenesis gene transduction studies in mice

Hiroaki Yoshida, Alyssa H. Hasty, Amy S. Major, Hiroyuki Ishiguro, Yan Ru Su, Linda A. Gleaves, Vladimir R. Babaev, MacRae F. Linton, Sergio Fazio

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background-We recently used a bone marrow-based gene therapy approach to show that small amounts of retrovirus-derived human apolipoprotein E3 (apoE3) produced by macrophages are protective against early atherosclerosis in apoE-deficient mice. Methods and Results-In the present study, we evaluated whether the effect produced by macrophage-derived apoE3 is related to its ability to bind cellular membranes. To this end, we used apoE2 and apoEcys 142, dysfunctional human variants with reduced binding to the LDL receptor or to heparan sulfate proteoglycans, respectively. ApoE-deficient mice, 5 weeks of age, received transplants of apoE-/- bone marrow cells transduced with either parental retrovirus or apoE3, apoE2, or apoEcys142 retroviral vectors. Human apoE was detected by ELISA in the serum of apoE3, apoE2, and apoEcys142 mice as early as 4 weeks after bone marrow transplantation, and at 8 weeks, plasma apoE levels were 55.5±20.3, 50.5±8.7, and 15.3±7.3 μg/dL, respectively. In all groups, cholesterol levels increased with age but were not affected by apoE expression. As previously demonstrated, the lesion area in male apoE3 mice (3808±2224 μm2/section) was 40% smaller than that in control mice (6503±3475 μm2/section). In apoE2 mice, however, the lesion area was similar to that of controls (5991±2771 μm2/section), and apoEcys142 mice showed an unexpected and significant increase in lesion size (10 320±6128 μm2/section). Thus, transplantation with marrow transfected with receptor binding-defective apoE variants did not replicate the antiatherogenic effect of apoE3. Conclusions-These data provide in vivo evidence suggesting that macrophage-derived apoE delays development of atherosclerosis through a receptor-dependent pathway.

Original languageEnglish (US)
Pages (from-to)2820-2825
Number of pages6
JournalCirculation
Volume104
Issue number23
StatePublished - Dec 4 2001
Externally publishedYes

Fingerprint

Apolipoprotein E3
Apolipoproteins E
Atherosclerosis
Protein Isoforms
Apolipoprotein E2
Genes
Macrophages
Retroviridae
Bone Marrow
Heparan Sulfate Proteoglycans
LDL Receptors
Bone Marrow Transplantation
Bone Marrow Cells
Genetic Therapy
Transplantation
Enzyme-Linked Immunosorbent Assay
Cholesterol
Transplants
Membranes
Serum

Keywords

  • Apolipoproteins
  • Lipoproteins
  • Proteoglycans
  • Receptors

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Yoshida, H., Hasty, A. H., Major, A. S., Ishiguro, H., Su, Y. R., Gleaves, L. A., ... Fazio, S. (2001). Isoform-specific effects of apolipoprotein E on atherogenesis gene transduction studies in mice. Circulation, 104(23), 2820-2825.

Isoform-specific effects of apolipoprotein E on atherogenesis gene transduction studies in mice. / Yoshida, Hiroaki; Hasty, Alyssa H.; Major, Amy S.; Ishiguro, Hiroyuki; Su, Yan Ru; Gleaves, Linda A.; Babaev, Vladimir R.; Linton, MacRae F.; Fazio, Sergio.

In: Circulation, Vol. 104, No. 23, 04.12.2001, p. 2820-2825.

Research output: Contribution to journalArticle

Yoshida, H, Hasty, AH, Major, AS, Ishiguro, H, Su, YR, Gleaves, LA, Babaev, VR, Linton, MF & Fazio, S 2001, 'Isoform-specific effects of apolipoprotein E on atherogenesis gene transduction studies in mice', Circulation, vol. 104, no. 23, pp. 2820-2825.
Yoshida H, Hasty AH, Major AS, Ishiguro H, Su YR, Gleaves LA et al. Isoform-specific effects of apolipoprotein E on atherogenesis gene transduction studies in mice. Circulation. 2001 Dec 4;104(23):2820-2825.
Yoshida, Hiroaki ; Hasty, Alyssa H. ; Major, Amy S. ; Ishiguro, Hiroyuki ; Su, Yan Ru ; Gleaves, Linda A. ; Babaev, Vladimir R. ; Linton, MacRae F. ; Fazio, Sergio. / Isoform-specific effects of apolipoprotein E on atherogenesis gene transduction studies in mice. In: Circulation. 2001 ; Vol. 104, No. 23. pp. 2820-2825.
@article{a6be47fe5497465b96078accaf681ec3,
title = "Isoform-specific effects of apolipoprotein E on atherogenesis gene transduction studies in mice",
abstract = "Background-We recently used a bone marrow-based gene therapy approach to show that small amounts of retrovirus-derived human apolipoprotein E3 (apoE3) produced by macrophages are protective against early atherosclerosis in apoE-deficient mice. Methods and Results-In the present study, we evaluated whether the effect produced by macrophage-derived apoE3 is related to its ability to bind cellular membranes. To this end, we used apoE2 and apoEcys 142, dysfunctional human variants with reduced binding to the LDL receptor or to heparan sulfate proteoglycans, respectively. ApoE-deficient mice, 5 weeks of age, received transplants of apoE-/- bone marrow cells transduced with either parental retrovirus or apoE3, apoE2, or apoEcys142 retroviral vectors. Human apoE was detected by ELISA in the serum of apoE3, apoE2, and apoEcys142 mice as early as 4 weeks after bone marrow transplantation, and at 8 weeks, plasma apoE levels were 55.5±20.3, 50.5±8.7, and 15.3±7.3 μg/dL, respectively. In all groups, cholesterol levels increased with age but were not affected by apoE expression. As previously demonstrated, the lesion area in male apoE3 mice (3808±2224 μm2/section) was 40{\%} smaller than that in control mice (6503±3475 μm2/section). In apoE2 mice, however, the lesion area was similar to that of controls (5991±2771 μm2/section), and apoEcys142 mice showed an unexpected and significant increase in lesion size (10 320±6128 μm2/section). Thus, transplantation with marrow transfected with receptor binding-defective apoE variants did not replicate the antiatherogenic effect of apoE3. Conclusions-These data provide in vivo evidence suggesting that macrophage-derived apoE delays development of atherosclerosis through a receptor-dependent pathway.",
keywords = "Apolipoproteins, Lipoproteins, Proteoglycans, Receptors",
author = "Hiroaki Yoshida and Hasty, {Alyssa H.} and Major, {Amy S.} and Hiroyuki Ishiguro and Su, {Yan Ru} and Gleaves, {Linda A.} and Babaev, {Vladimir R.} and Linton, {MacRae F.} and Sergio Fazio",
year = "2001",
month = "12",
day = "4",
language = "English (US)",
volume = "104",
pages = "2820--2825",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

TY - JOUR

T1 - Isoform-specific effects of apolipoprotein E on atherogenesis gene transduction studies in mice

AU - Yoshida, Hiroaki

AU - Hasty, Alyssa H.

AU - Major, Amy S.

AU - Ishiguro, Hiroyuki

AU - Su, Yan Ru

AU - Gleaves, Linda A.

AU - Babaev, Vladimir R.

AU - Linton, MacRae F.

AU - Fazio, Sergio

PY - 2001/12/4

Y1 - 2001/12/4

N2 - Background-We recently used a bone marrow-based gene therapy approach to show that small amounts of retrovirus-derived human apolipoprotein E3 (apoE3) produced by macrophages are protective against early atherosclerosis in apoE-deficient mice. Methods and Results-In the present study, we evaluated whether the effect produced by macrophage-derived apoE3 is related to its ability to bind cellular membranes. To this end, we used apoE2 and apoEcys 142, dysfunctional human variants with reduced binding to the LDL receptor or to heparan sulfate proteoglycans, respectively. ApoE-deficient mice, 5 weeks of age, received transplants of apoE-/- bone marrow cells transduced with either parental retrovirus or apoE3, apoE2, or apoEcys142 retroviral vectors. Human apoE was detected by ELISA in the serum of apoE3, apoE2, and apoEcys142 mice as early as 4 weeks after bone marrow transplantation, and at 8 weeks, plasma apoE levels were 55.5±20.3, 50.5±8.7, and 15.3±7.3 μg/dL, respectively. In all groups, cholesterol levels increased with age but were not affected by apoE expression. As previously demonstrated, the lesion area in male apoE3 mice (3808±2224 μm2/section) was 40% smaller than that in control mice (6503±3475 μm2/section). In apoE2 mice, however, the lesion area was similar to that of controls (5991±2771 μm2/section), and apoEcys142 mice showed an unexpected and significant increase in lesion size (10 320±6128 μm2/section). Thus, transplantation with marrow transfected with receptor binding-defective apoE variants did not replicate the antiatherogenic effect of apoE3. Conclusions-These data provide in vivo evidence suggesting that macrophage-derived apoE delays development of atherosclerosis through a receptor-dependent pathway.

AB - Background-We recently used a bone marrow-based gene therapy approach to show that small amounts of retrovirus-derived human apolipoprotein E3 (apoE3) produced by macrophages are protective against early atherosclerosis in apoE-deficient mice. Methods and Results-In the present study, we evaluated whether the effect produced by macrophage-derived apoE3 is related to its ability to bind cellular membranes. To this end, we used apoE2 and apoEcys 142, dysfunctional human variants with reduced binding to the LDL receptor or to heparan sulfate proteoglycans, respectively. ApoE-deficient mice, 5 weeks of age, received transplants of apoE-/- bone marrow cells transduced with either parental retrovirus or apoE3, apoE2, or apoEcys142 retroviral vectors. Human apoE was detected by ELISA in the serum of apoE3, apoE2, and apoEcys142 mice as early as 4 weeks after bone marrow transplantation, and at 8 weeks, plasma apoE levels were 55.5±20.3, 50.5±8.7, and 15.3±7.3 μg/dL, respectively. In all groups, cholesterol levels increased with age but were not affected by apoE expression. As previously demonstrated, the lesion area in male apoE3 mice (3808±2224 μm2/section) was 40% smaller than that in control mice (6503±3475 μm2/section). In apoE2 mice, however, the lesion area was similar to that of controls (5991±2771 μm2/section), and apoEcys142 mice showed an unexpected and significant increase in lesion size (10 320±6128 μm2/section). Thus, transplantation with marrow transfected with receptor binding-defective apoE variants did not replicate the antiatherogenic effect of apoE3. Conclusions-These data provide in vivo evidence suggesting that macrophage-derived apoE delays development of atherosclerosis through a receptor-dependent pathway.

KW - Apolipoproteins

KW - Lipoproteins

KW - Proteoglycans

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=0035808002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035808002&partnerID=8YFLogxK

M3 - Article

C2 - 11733401

AN - SCOPUS:0035808002

VL - 104

SP - 2820

EP - 2825

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 23

ER -